에 대한 최신 뉴스 Biohaven (NYSE:BHVN) 주식

Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Pharma Hldgs

Biohaven Pharmaceutical

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

BHVN

TRAK

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 어큐이티 브랜즈(NYSE:AYI)가 분기별 실적을 주당 $4.28, 매출 $10.2억 달러로 예상하고 있으며, 시장 개장 전에 실적을 발표할 것이라고 전했다. 어큐이티 브랜즈의 주식은 애프터 마켓에서 1.7% 상승하여 $279.94에 거래되었다.

화요일 주목해야 할 주식: 어큐이티 브랜즈, 나이키, 리포시트랙 그리고 2종목

Biotech

Equities

Health Care

Global

GPCR

RHHBY

스트럭처 테라퓨틱스(NASDAQ:GPCR)의 주식은 비만 치료제 시장에서 잠재적인 승자로 지목되었다. JP모건은 주식에 상당한 상승 잠재력을 부여했다. What Happened: JP모은 생명공학 회사인 스트럭처 테라퓨틱스에 대해 &#34;비중확대(Overweight)&#34; 등급과 목표 주가를 65달러로 이 주식의 커버리지를 시작했다. 이는 현재 수준보다 80%의 잠재적 상승여력을 나타낸다. 비지니스 인사이더(Business Insider)에 따르면 은행은 빠르게 성장하는 GLP-1 체중 감량 약물 시장에서 스트럭처 테라퓨틱스를 주요 업체로 확인했다.

스트럭처 테라퓨틱스 주식은 비만 치료제 시장의 돌파구로 80% 상승 예상: JP모건

Biohaven Ltd

Wedbush analyst Daniel Ives reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and maintains $400 price target.

Price Target

Reiteration

Analyst Ratings

TSLA

Wedbush Reiterates Outperform on Tesla, Maintains $400 Price Target

TOKYO -- U.S. business software provider ServiceNow plans to invest $2 billion in Japan over the next few years to expand its data center operation and local office, CEO Bill McDermott has told&nbsp;Nikkei.
Part of the spending will go toward data center expansion to accommodate the increase in client companies and enhance&nbsp;services that use generative artificial intelligence.
<a href="https://asia.nikkei.com/Business/Technology/U.S.-tech-firm-ServiceNow-to-spend-2bn-on-Japan-data-center-push" title="https://asia.nikkei.com/Business/Technology/U.S.-tech-firm-ServiceNow-to-spend-2bn-on-Japan-data-center-push">https://asia.nikkei.com/Business/Technology/U.S.-tech-firm-ServiceNow-to-spend-2bn-on-Japan-data-center-push</a>

'U.S. tech firm ServiceNow to spend $2bn on Japan data center push' -Nikkei

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $20 to $23.

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $23

BMO Capital analyst Kelly Bania maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Market Perform and lowers the price target from $90 to $80.

BMO Capital Maintains Market Perform on Dollar Gen, Lowers Price Target to $80

Barclays analyst John Coffey maintains StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) with a Equal-Weight and lowers the price target from $13 to $12.

STNE

Barclays Maintains Equal-Weight on StoneCo, Lowers Price Target to $12

BMO Capital analyst Kelly Bania maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and lowers the price target from $68 to $65.

DLTR

BMO Capital Maintains Market Perform on Dollar Tree, Lowers Price Target to $65

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Neutral and maintains $14 price target.

NTLA

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $14 Price Target

Barclays analyst Simon Coles maintains Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Overweight and raises the price target from $215 to $240.

Barclays Maintains Overweight on Taiwan Semiconductor, Raises Price Target to $240

BMO Capital analyst Kelly Bania maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Outperform and raises the price target from $980 to $1075.

COST

BMO Capital Maintains Outperform on Costco Wholesale, Raises Price Target to $1075

PLAG

Planet Green Holdings Shares Halted To The Downside; Stock Now Down -4.42%

Wedbush analyst Nick Setyan maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Outperform and lowers the price target from $60 to $50.

JACK

Wedbush Maintains Outperform on Jack In The Box, Lowers Price Target to $50

BMO Capital analyst Kelly Bania maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $80 to $100.

BMO Capital Maintains Outperform on Walmart, Raises Price Target to $100

General

BBIO

BridgeBio Pharma Says The Continued Curve Separation Of The Composite Endpoint Of ACM And Recurrent Cardiovascular-Related Hospitalizations Emphasizes The Importance Of Early Intervention Resulting In Early And Sustained Clinical Benefits, With Acoramidis Demonstrating 46% And 48% Reductions In The Composite Endpoint Of ACM And Recurrent CVH At Months 36 And 42, Respectively

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension
- The continued curve separation of the composite endpoint of ACM and recurrent cardiovascular-related hospitalizations (CVH) emphasizes the importance of early intervention resulting in early and sustained clinical benefits, with acoramidis demonstrating 46% (p&lt;0.0001) and 48% (p&lt;0.0001) reductions in the composite endpoint of ACM and recurrent CVH at Months 36 and 42, respectively
- The preliminary results from this ongoing OLE study were also <a href="https://www.globenewswire.com/Tracker?data=nVrCQc_8jzuW0us-lfgFaR1qVTq_ZKK094j0nAXwGOzjpiNvmiPryHA11xPFHhBaYgKeFEBHeF4VNpSc_nsfEV21llyp7gkCWZiQNzvNSBAxj8g76mpygGVWg7b6bJ3rrNNv9OwALUuytnCVMDnjfDM4znS65x927SjyqqRsPQ4YxLUlnW0b98_MjiwYp5E1">simultaneously published in&nbsp;Circulation</a>
- A New Drug Application for acoramidis for the treatment of ATTR-CM is currently under review with the FDA, with a PDUFA action date of November 29, 2024
PALO ALTO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) ("BridgeBio" or the "Company"), a&nbsp;new type of biopharmaceutical company focused on genetic diseases, presented positive initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association (AHA) Scientific Sessions. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational, near-complete, orally-administered, small molecule stabilizer of TTR. The preliminary results from this ongoing OLE study were also <a href="https://www.globenewswire.com/Tracker?data=nVrCQc_8jzuW0us-lfgFaR1qVTq_ZKK094j0nAXwGOzjpiNvmiPryHA11xPFHhBaeIlDqZKG7OqhCoe56sd754bjgDVGcOiJ2s8HyuUyG7NflQCmEEQ3lIVaCQMHailwHLZaiAioFHGbJQ3YCr7zBvPyWKH7hTdh2uwLa8ooRVkFlNr8o40ZFfvRncYmj6k3">simultaneously published in&nbsp;Circulation</a>. The OLE study involves 330 participants who completed the 30-month ATTRibute-CM Phase 3 study.

BridgeBio Pharma Presented Initial Outcomes From The ATTRibute-CM Open-label Extension Study Of Acoramidis In ATTR-CM At The AHA Scientific Sessions; Acoramidis Demonstrated The Earliest Known Time To Separation In Cardiovascular Outcomes In The  ATTRibute-CM Study (3 Months), With Statistically Significant Risk Reduction Of 36% On All-Cause Mortality Alone At Month 36 Within The Open Label Extension

BMO Capital analyst James Thalacker maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Outperform and lowers the price target from $166 to $159.

BMO Capital Maintains Outperform on Entergy, Lowers Price Target to $159

Benchmark analyst Nathan Martin reiterates Arch Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCH#NYSE">ARCH</a>) with a Buy and maintains $180 price target.

ARCH

Benchmark Reiterates Buy on Arch Resources, Maintains $180 Price Target

Many Senate Republicans want the House Ethics Committee report on Matt Gaetz to be released. Gaetz is a close ally of President-elect Donald Trump.
<a href="https://www.cnbc.com/2024/11/18/trump-ag-matt-gaetz-house-ethics-panel-report-meeting.html" title="https://www.cnbc.com/2024/11/18/trump-ag-matt-gaetz-house-ethics-panel-report-meeting.html">https://www.cnbc.com/2024/11/18/trump-ag-matt-gaetz-house-ethics-panel-report-meeting.html</a> &nbsp;

Politics

'House Ethics panel to meet on Trump attorney general pick Matt Gaetz report Wednesday' - CNBC

Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) promises discounts and exclusive offers <a href="https://www.benzinga.com/topic/holidays">this holiday shopping season</a>. 
The retailer aims to offer an enhanced shopping experience, both online and in stores, with early access for Walmart+ members.
Starting at noon ET on Nov. 25, Walmart+ members will get a head start on Black Friday deals before the general public at 5 p.m. ET. Walmart&#8217;s holiday sales will feature steep discounts across top categories like electronics, toys, and fashion, with doorbuster deals available in-store from 6 a.m. local time on Black Friday.
Walmart promises savings across brands like Reebok, Michael Kors, and Dyson. Highlighted deals include: 
<ul>
<li>Dyson V11 Extra Cordless Vacuum Cleaner for $349.99, saving shoppers $250 off the regular price. </li>
<li>A TCL 65-inch 4K UHD Smart TV for $228, a discount of $301.</li>
<li>A Restored Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) MacBook Air bundle priced at $194, saving $81.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/earnings/24/11/42031958/niu-q3-earnings-scooter-volume-up-but-price-drops-and-margins-tighten-strong-q4-outlook-and-more" target="_blank" rel="noreferrer noopener">Niu Q3 Earnings: Scooter Volume Up, But Price Drops And Margins Tighten, Strong Q4 Outlook And More</a>
Sign-ups are available for a discounted annual fee of $49 until Dec. 2. This membership perk provides early shopping windows for Black Friday and Cyber Monday events and other exclusive offers throughout the holiday season.
Walmart&#8217;s Cyber Monday deals will start on Sunday, Dec. 1, at 5 p.m. ET for Walmart+ members and at 8 p.m. ET for all customers. 
Featured deals include: 
<ul>
<li>The $898 Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) 75-inch BRAVIA 4K HDR LED TV, a savings of $600.</li>
<li>The $98 Ninja Grand Kitchen System and the $48.98 LEGO Star Wars Darth Vader Helmet.</li>
</ul>
Walmart has enhanced its holiday shopping features, offering customers a personalized search experience, expanded delivery options, and the ability to schedule delivery for large items. 
This year, Walmart also partnered with Angi for convenient installation services, including home décor and TV setups, catering to various holiday needs.
Amazon.Com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) U.S. sales on Cyber Monday reached <a href="https://www.benzinga.com/news/24/10/41185124/amazon-to-boost-workforce-by-250k-for-2024-holidays-joining-retail-hiring-surge">$12.4 billion in 2023</a>, rising 9.6% and surpassing the $12 billion forecast. Total online sales for Cyber Week hit $38 billion, exceeding the $37.2 billion estimate.
Bank of America analyst Robert Ohmes predicted strong third-quarter results.
Ohmes expects Walmart&#8217;s third-quarter earnings per share to reach $0.52, driven by grocery and <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41913981/what-to-expect-from-walmarts-q3-earnings" rel="noreferrer noopener">health/wellness sales growth</a>. Walmart&#8217;s store remodels, online product expansion, and express delivery upgrades boost sales and customer loyalty. Despite a shorter holiday season, Walmart&#8217;s strong digital and omni-channel offerings could see increased online sales.
Walmart faces risks from Trump&#8217;s tariff plans, which may raise costs and challenge its low-price strategy.
Tax cuts enable Walmart to reinvest in technology, strengthening its edge against rivals like Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
Investors can gain exposure to Walmart through SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>).
Price Action: WMT stock is up 0.53% at $84.70 premarket at last check Monday. Walmart stock surged 59% year-to-date.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41978712/asml-projects-revenue-surge-to-63-billion-by-2030-eyes-ai-and-chip-market-boom" target="_blank" rel="noreferrer noopener">ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom</a></li>
</ul>

AAPL

AMZN

Sony Group Corporation American Depositary Shares

SONY

Walmart Gears Up For Black Friday, Cyber Monday Specials: Major Discounts On Apple MacBooks, Sony TVs

Deep-pocketed investors have adopted a bullish approach towards Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 28 extraordinary options activities for Hims &amp; Hers Health. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 71% leaning bullish and 14% bearish. Among these notable options, 12 are puts, totaling $960,282, and 16 are calls, amounting to $827,190.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $15.0 and $42.0 for Hims &amp; Hers Health, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Hims &amp; Hers Health's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Hims &amp; Hers Health's whale activity within a strike price range from $15.0 to $42.0 in the last 30 days. 
<h3>Hims &amp; Hers Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731946560_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$25.00</td>
<td>$208.8K</td>
<td>3.5K</td>
<td>1.7K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$1.5</td>
<td>$1.4</td>
<td>$1.44</td>
<td>$20.50</td>
<td>$147.0K</td>
<td>2.0K</td>
<td>2.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.35</td>
<td>$1.25</td>
<td>$1.34</td>
<td>$28.00</td>
<td>$132.7K</td>
<td>2.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.45</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$20.00</td>
<td>$120.0K</td>
<td>6.2K</td>
<td>989</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$2.5</td>
<td>$2.4</td>
<td>$2.45</td>
<td>$21.00</td>
<td>$113.9K</td>
<td>5.2K</td>
<td>480</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
In light of the recent options history for Hims &amp; Hers Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Hims &amp; Hers Health</h3>
<ul>
<li>Currently trading with a volume of 10,964,198, the HIMS's price is up by 12.73%, now at $21.78. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 98 days.</li>
</ul>
<h3>What Analysts Are Saying About Hims &amp; Hers Health</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $23.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Underperform, setting a price target of $18. 
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $21. 
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on Hims &amp; Hers Health, maintaining a target price of $28. 
&#x2A; An analyst from Deutsche Bank has decided to maintain their Hold rating on Hims &amp; Hers Health, which currently sits at a price target of $27. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Hims &amp; Hers Health with a target price of $25. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Hims &amp; Hers Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Unpacking the Latest Options Trading Trends in Hims & Hers Health

<a href="https://www.benzinga.com/24/11/41947081/kevin-oleary-says-great-entrepreneurs-and-great-leaders-want-to-get-up-in-the-morning-and-get-to-work-heres-what-he-says-drives-them">Kevin O&#8217;Leary</a> recently appeared on The Daniela Cambone Show, where he discussed the current state of the U.S. energy sector and broader market trends. O&#8217;Leary, known for his outspoken views on business and investment, shared his thoughts on how regulatory changes under the Biden-Harris administration have impacted the economy, particularly in energy and how markets are reacting now.
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai-2">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in the next few days</a>!</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>
O&#8217;Leary made it clear that a lot of the recent market movement is due to what he sees as the lifting of &#8220;a trillion dollars worth of regulatory pressure.&#8221; Reflecting on the <a href="https://www.benzinga.com/personal-finance/24/11/42013651/is-trumps-second-term-going-to-affect-student-loan-borrowers-here-are-3-potential-changes">Trump administration</a>, he explained how previous deregulation policies benefited multiple industries, especially energy.&nbsp;
"Trump stripped away a lot of the regulation and energy was a huge beneficiary," O&#8217;Leary said. According to him, this helped energy companies thrive, creating a more open environment for growth and expansion.
However, O&#8217;Leary also pointed out how the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41976407/ben-horowitz-the-biden-regulators-lied-about-crypto">Biden administration&#8217;s policies</a> reversed some of that. He specifically mentioned how regulations were added to the energy sector, which, in his view, made things harder.&nbsp;
Trending: This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 —<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a>
"Biden-Harris, whether you liked them or not, added a lot of layers of administration and regulation," he said. He noted that natural gas exports were halted and new energy permits became harder to obtain. According to O&#8217;Leary, these measures had a cooling effect on the energy sector. "They made it difficult for companies to expand or even get new projects started," he added.
Despite these setbacks, O&#8217;Leary believes the market mood is improving. &#8220;The market's celebrating a more positive view of expansion,&#8221; he said. This shift is partly due to the hope that the regulatory environment might become more business-friendly. With the lifting of certain restrictions, O'Leary believes energy companies and other sectors are seeing more growth opportunities again.
O&#8217;Leary also discussed other sectors benefiting from changes in the regulatory landscape, including the <a href="https://www.benzinga.com/media/24/11/42022531/cathie-wood-backs-elon-musks-2-trillion-doge-initiative-says-tesla-ceos-access-to-proprietary-data-and-ai-gives-him-an-edge">cryptocurrency market</a>. In particular, he commented on the recent rumors surrounding the Commodity Futures Trading Commission (CFTC) potentially taking over crypto regulation from the Securities and Exchange Commission (SEC).&nbsp;
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
O&#8217;Leary remarked that the SEC's litigious approach to regulation may have hindered growth in the digital currency space and that fewer regulations would have been positive.
O&#8217;Leary also shared his optimism about technology and finance, particularly digital payments. "I'm a big believer in digital payment systems beyond just tokens and Bitcoin," he said. He sees these systems as essential for the future of global finance, offering potential far beyond what we currently see in the world of cryptocurrencies.
In a final reflection, O&#8217;Leary noted that democracy has a way of correcting itself. "When things get too crazy, to the left, to the right, it somehow figures out how to fix itself," he said.&nbsp;
Read Next:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes in a few days.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Startups

Kevin O'Leary: 'Biden-Harris Regulations Held Back Energy, But Markets Now Celebrate Expansion'

Pre-earnings options volume in Biohaven (BHVN) is normal with calls leading puts 8:7. Implied volatility suggests the market is anticipating a move...

Biohaven options imply 19.6% move in share price post-earnings

Argenx upgraded at Wolfe on myasthenia gravis dominance

Biohaven Ltd. (BHVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tyler Van Buren fr...

Biohaven Ltd.'s Strategic Advancements and Promising Pipeline Drive Buy Rating

Biohaven Non-GAAP EPS of -$1.74 misses by $0.24

TD Cowen analyst Ken Cacciatore raised the firm's price target on Biohaven (BHVN) to $75 from $55 and keeps a Buy rating on the shares. The firm sa...

Biohaven price target raised to $75 from $55 at TD Cowen

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price ...

Piper Sandler Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) today. The company's shares ope...

Bank of America Securities Remains a Buy on Biohaven Ltd. (BHVN)

Douglas Tsao, an analyst from H.C. Wainwright, maintained the Buy rating on Biohaven Ltd. (BHVN – Research Report). The associated price target rem...

Promising Therapeutic Advancements Propel Biohaven Ltd. to Buy Rating: Analyst Douglas Tsao Highlights Key Developments in SCA, SMA, and Migraine Treatments

Analyst Marc Goodman from Leerink Partners maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target at $60.00...

Biohaven Ltd.: Strong Buy Rating Driven by Promising Pipeline Progress and Strategic Resubmissions

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price targe...

Biohaven Ltd. (BHVN) Receives a Buy from Morgan Stanley

ARGX

IMVT

Press Releases

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Management

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Offerings

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

BNTC

Arcellx

ADMA Biologics

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alkermes

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Dyne Therapeutics

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

ImmunityBio

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viking Therapeutics

HC Wainwright & Co.

TD Cowen

RBC Capital

JP Morgan

Bernstein

화요일 오전 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
1. 월스트리트는 어큐이티 브랜즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>)가 분기별 실적을 주당 $4.28, 매출 $10.2억 달러로 예상하고 있으며, 시장 개장 전에 실적을 발표할 것이라고 전했다. 어큐이티 브랜즈의 주식은 애프터 마켓에서 1.7% 상승하여 $279.94에 거래되었다.
2. 리포시트랙(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>)은 4분기 재무 실적이 예상보다 좋았으며 분기 배당금을 10% 인상했다고 발표했다. 리포시트랙의 주식은 애프터 마켓에서 4.6% 상승하여 $19.32에 거래되었다.
3. 애널리스트들은 맥코믹 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>)가 최근 분기 매출 $167만, 주당 67센트의 이익을 기록했다. 이 회사는 시장이 열리기 전에 실적을 발표할 예정이다. 맥코믹의 주가는 시간외 거래에서 0.4% 상승한 $82.60을 기록했다.
프리마켓 보도를 확인하시려면 <a href="https://www.benzinga.com/premarket/">여기</a>를 클릭하세요.
4. 바이오헤이븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)는 2억 5천만 달러 규모의 보통주 공모를 제안했다고 발표했다. 바이오헤이븐의 주식은 애프터 마켓에서 1.9% 하락하여 $49.00에 거래되었다.
5. 애널리스트들은 나이키(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>)가 마감 후 분기 매출 $1,165만, 주당 52센트의 분기 이익을 게시할 예정이다. 나이키의 주가는 시간외 거래에서 0.1% 하락한 $88.31를 기록했다.
이것을 확인하세요:
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">짐 크레이머가 선정한 중국 경기 부양책 열풍을 타고 갈 3개 주식</a></li>
</ul>
사진 제공: Shutterstock

스트럭처 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>)의 주식은 비만 치료제 시장에서 잠재적인 승자로 지목되었다. JP모건은 주식에 상당한 상승 잠재력을 부여했다.
What Happened: JP모은 생명공학 회사인 스트럭처 테라퓨틱스에 대해 &#8220;비중확대(Overweight)&#8221; 등급과 목표 주가를 65달러로 이 주식의 커버리지를 시작했다. 이는 현재 수준보다 80%의 잠재적 상승여력을 나타낸다. 비지니스 인사이더(Business Insider)에 따르면 은행은 빠르게 성장하는 GLP-1 체중 감량 약물 시장에서 스트럭처 테라퓨틱스를 주요 업체로 확인했다.
스트럭처 테라퓨틱스는 GLP-1 체중 감량 시장을 겨냥해 고안된 경구용 알약인 &#8216;1290&#8217;이라는 약물 후보를 개발하고 있다. 이 약물은 잠재적으로 경쟁사보다 1~2년 앞서 시장에 출시될 수 있는 소분자 제제를 기반으로 한다.
이 약은 다른 경구용 체중 감량 약물 후보와 차별화되어 안전성에 큰 우려가 없는 환자에게 상당한 체중 감량 효과를 제공할 것으로 기대된다.
"우리는 전례 없이 큰 시장에서 구강 시장에서 GPCR의 시장 점유율이 시간이 지남에 따라 5%에 접근할 수 있다고 생각한다. 전체적으로 우리는 1290/스트럭처가 T2D/비만 시장에 참여하려는 대규모 바이오제약 회사들에게 매력적인 파트너십 기회가 될 수 있다고 생각한다"라고 JP모건이 말했다.
JP모건은 스트럭처 테라퓨틱스의 경구용 GLP-1 체중 감량 약물 후보가 2035년까지 10억 달러 이상의 최고 매출을 올릴 수 있을 것으로 믿고 있다. 이 회사는 2023년 2월에 상장되었다.
참조: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38910906/bitcoin-dogecoin-ethereum-retrace-on-profit-taking-by-retail-investors-analyst-predicts-pa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">비트코인, 도지코인, 이더리움은 소매 투자자들의 이익 실현에 하락</a>
Why It Matters: 비만 치료제 시장은 중요한 발전을 보이고 있다. 최근 로슈(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)은 이중 GLP-1/GIP 수용체 작용제 CT-388의 1b상 시험에서 유망한 결과를 발표하여 비만 치료 시장에서 <a href="https://www.benzinga.com/general/biotech/24/05/38878582/roche-to-ride-booming-obesity-treatment-market-with-newly-acquired-drug-candidate">상당한 잠재력</a>을 나타냈다.
또한 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 중국에서 당뇨병 치료제 티르제파티드(tirzepatide)에 대한 승인을 확보하여 중요한 아시아 시장에서 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와의 <a href="https://www.benzinga.com/general/biotech/24/05/38941485/eli-lilly-secures-china-nod-for-popular-weight-lossdiabetes-drug-tirzepatide">경쟁</a>이 치열해질 수 있는 발판을 마련했다.
앞서 바이오헤븐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)은 체중 감량을 돕는 동시에 근육 손실을 예방할 수 있는 실험 약물인 탈데프그로벱 알파(taldefgrobep alfa)(BHVN-2000)를 통해 비만 치료제 시장에 대한 <a href="https://www.benzinga.com/general/biotech/24/03/37942782/obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff">다른</a> 접근 방식을 강조했다.
다음 읽기: <a href="https://www.benzinga.com/tech/24/05/38919616/apples-groundbreaking-iphone-16-could-spark-another-stock-surge-building-on-an-800-growth-over-the-l?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">애플, 6월 WWDC에서 아이폰 13 시리즈 공개 예고</a>
AI를 통해 생산된 이미지
<hr class="wp-block-separator has-alpha-channel-opacity" />
Benzinga Neuro의 기술, <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a> 편집
<hr class="wp-block-separator has-alpha-channel-opacity" />
GPT-4 기반의 Benzinga Neuro 콘텐츠 생성 시스템은 광벤짜 생태계의 네이티브 데이터, API 등을 활용하여 포괄적이고 시의적절한 이야기를 제공합니다. <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">더 알아보기</a>.
<hr class="wp-block-separator has-alpha-channel-opacity" />

Comments

Biohaven

뉴스

에 대한 최신 뉴스 Biohaven (NYSE:BHVN) 주식

화요일, 10월 01, 2024

수요일, 5월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌